Clinical News

Neratinib plus fulvestrant plus trastzuzumab is a promising combination for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (mBC): results from the phase II SUMMIT trial


Abstract: There is a promising combination of neratinib plus fulvestrant plus trastzuzumab (N+F+T) to patients with HR+/HER2-/HER2mut metastatic breast cancer, who pretreated with CDK4/6 inhibitor.
In breast cancer, HER2 mutations vary in frequency from 2% to 8%, depending on disease stage and histology and are associated with poor prognosis. Neratinib is a second-generation, pan-HER TKI that irreversibly binds to the ATP pocket of the tyrosine kinase domain of epidermal growth factor receptor (EGFR), HER2, and HER4. SUMMIT trail enrolled 45 patients with HR+, HER2-negative MBC with activating HER2 mutations who had previously been treated with a CDK4/6 inhibitor. The result of SUMMIT showed that objective response rate (ORR) and clinical benefit rate (CBR) of the N+F+T regimen reached 38% and 47%, respectively. Duration of response (DoR) was 14.4 months. In addition, it’s worth mention that the ORR of several HER2 allelic variants was 50% in V777L, 40% in L755S/P, 50% in S310F, 36% in exon 20 insertion. According to SUMMIT trail and another neratinib-related trial – MutHER, the National Comprehensive Cancer Network (NCCN) advises to consider neratinib ± fulvestrant / trastzuzumab and neratinib ± fulvestrant in certain circumstances for patients with HR+ or HR-/HER2- metastatic breast cancer with HER2 activating mutations who had received CDK4/6 inhibitor. (This recommendation was also added in NCCN Clinical Practice Guidelines in breast cancer version 1.2023, and the recommended evidence level is category 2B.)

  1. Komal L. Jhaveri, Jonathan W. Goldman, et al. Journal of Clinical Oncology. 2022; 40, no. 16_suppl:1028-1028.
  2. Eli LD, Kavuri SM. Cancer Drug Resist. 2022;5(4):873-881.
  3. NCCN Clinical Practice Guidelines. Breast Cancer. Version 1.2023